A study presented at the European Society for Radiotherapy and Oncology 35, ongoing in Turin, Italy, has shown that women younger than 45 years, diagnosed with early stage breast cancer, who chose breast conservation therapy followed by radiation, over mastectomy, had a significantly greater risk of local disease recurrence.
Oral anticancer agents are being launched at significantly higher prices compared with a decade ago, which can prove a barrier to patient access, according to a new analysis published in JAMA Oncology.
Bruce A. Feinberg, DO, Alan Balch, PhD, and Ted Okon, MBA, discuss how considerations between healthcare professionals and patients may differ in the treatment decision process and highlight how components such as healthcare costs challenge value-based care.
A small study in 30 patients with advanced B-cell acute lymphoblastic leukemia has further strengthened the faith in the potential of chimeric antigen receptor or CAR-T cell therapy.
A company in Canada, Biolyse Pharma, has offered to manufacture a generic version of enzalutamide at a significantly lower price than what CMS paid in 2014.


May 15-19, 2015
New Orleans, LA
May 29-June 2, 2015
Chicago, IL
June 11-14, 2015
Vienna, Austria
June 17-20, 2015
Lugano, Switzerland
Diabetes Compendium
Oncology Compendium
Reimbursement Compendium
HF Compendium